Abbott not going to make any kind of annoucement on P2 Fibroids so we will all be quessing what the results are.
Elagolix for Endo P3 top line results where scheduled for Y/E 2013 so they have slipped into 2014????
IMO, Abbott has not been the best partner for NBIX but it was the only partner that was willing to do UF along with Endo. Their womens health franchise is second to none but there have been significant delays in the development of Elagolix..
NBIX commented that they didn't know if Abbvie would discuss the UF data. If its positive you can bet they'll be presenting it at conferences and profiling it more aggressively on their analyst materials. Abbvie is all about their pipeline so I don't expect them to sit on solid data...they'll be promoting it. It's NBIX that can't release any data.
I think they said this on one of their quarterly conference calls...maybe two calls back?? It was just something along the lines of maybe Abbott will mention it and maybe they won't. They didn't know. However, my guess is that AbbVie will mention any positive phase 2 results because they need to drive up their stock price. I'm actually thinking about grabbing some AbbVie...love their pipeline. Am a big fan of the Galapagos JAK1 that AbbVie is developing for rheumatoid arthritis.
AbbVie is basically in a race against time because their cholesterol drug is going off patent and Humira goes off patent in 2017. They are looking for a replacement and if Phase 2 UF data is good then Elagolix could be one of their answers.
I am a very long term investor also....I was here initially when the focus was on CRF antagonists. That was a long time ago. It's nice to see NBIX resurrected after the insomnia debacle. Only a few companies can rebuild and make it back to the spotlight. I know there have been lots of changes but it's nice to see NBIX as a potential player again.